Published in J Natl Cancer Inst on June 29, 2009
Photodynamic therapy of cancer: an update. CA Cancer J Clin (2011) 6.08
Bending the cost curve in cancer care. N Engl J Med (2011) 5.02
Cancer drugs in the United States: Justum Pretium--the just price. J Clin Oncol (2013) 4.25
Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn (2010) 2.44
Drugs, cancer and end-of-life care: a case study of pharmaceuticalization? Soc Sci Med (2014) 2.03
When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst (2010) 1.95
Informing Canada's cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review. Curr Oncol (2013) 1.80
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol (2011) 1.65
How can bedside rationing be justified despite coexisting inefficiency? The need for 'benchmarks of efficiency'. J Med Ethics (2012) 1.44
Assessment of the therapeutic value of new medicines marketed in Australia. J Pharm Policy Pract (2013) 1.38
The economic pressures for biosimilar drug use in cancer medicine. Target Oncol (2012) 1.34
The value of progression-free survival to patients with advanced-stage cancer. Nat Rev Clin Oncol (2011) 1.33
Drug rechallenge and treatment beyond progression--implications for drug resistance. Nat Rev Clin Oncol (2013) 1.22
Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther (2013) 1.22
Medical expenditures of adult cancer survivors aged <65 years in the United States. Cancer (2010) 1.19
Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res (2011) 1.18
Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci (2012) 1.14
Expensive cancer drugs: a comparison between the United States and the United Kingdom. Milbank Q (2009) 1.12
The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol (2017) 1.04
Cost, coverage, and comparative effectiveness research: the critical issues for oncology. J Clin Oncol (2012) 1.01
Personalized cancer medicine--advances and socio-economic challenges. Nat Rev Clin Oncol (2011) 0.97
Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network. Lung Cancer (2012) 0.97
Evaluating a patient's request for life-prolonging treatment: an ethical framework. J Med Ethics (2012) 0.91
Clinical development of new drug-radiotherapy combinations. Nat Rev Clin Oncol (2016) 0.91
Antiangiogenic therapy for breast cancer. Breast Cancer Res (2010) 0.90
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol (2015) 0.90
"Just caring": can we afford the ethical and economic costs of circumventing cancer drug resistance? J Pers Med (2013) 0.89
Access to new cancer medicines in Australia: dispelling the myths and informing a public debate. J Pharm Policy Pract (2016) 0.89
What is the value of oncology medicines? Nat Biotechnol (2010) 0.89
Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. Int J Mol Sci (2013) 0.89
Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing. J Clin Endocrinol Metab (2011) 0.87
A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. Oncotarget (2014) 0.87
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front Pharmacol (2016) 0.85
Health care costs: how do we decide value? When do we decide? How do we particularize the decisions? Oncologist (2012) 0.84
Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab. Oncotarget (2014) 0.84
Therapy preferences in melanoma treatment--willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls. PLoS One (2014) 0.83
For the Sake of Justice: Should We Prioritize Rare Diseases? Health Care Anal (2017) 0.83
Quantitative medical cost-effectiveness analysis of molecular-targeting cancer drugs in Japan. Daru (2013) 0.83
International comparison of the factors influencing reimbursement of targeted anti-cancer drugs. BMC Health Serv Res (2014) 0.82
Management of osteoporosis among the elderly with other chronic medical conditions. Drugs Aging (2012) 0.82
Alignment of practice guidelines with targeted-therapy drug funding policies in Ontario. Curr Oncol (2013) 0.81
Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis. Support Care Cancer (2010) 0.81
Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Expert Rev Vaccines (2011) 0.80
The results with the addition of metronomic cyclophosphamide to palliative radiotherapy for the treatment of non-small cell lung carcinoma. Ann Transl Med (2015) 0.79
Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst (2017) 0.78
Does value mean quality? The payer's perspective. J Oncol Pract (2013) 0.78
Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer. ISRN Cell Biol (2012) 0.78
A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC). BMC Pulm Med (2014) 0.78
Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis. Breast Cancer Res Treat (2015) 0.78
Re: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst (2010) 0.77
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer (2014) 0.77
What is the role of maintenance therapy in the treatment of non-small cell lung cancer? Ther Adv Med Oncol (2010) 0.76
The cost of cancer care--balancing our duties to patients versus society: are they mutually exclusive? Oncologist (2013) 0.76
Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influence of funding. BMJ Open (2017) 0.75
Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future. Front Pharmacol (2017) 0.75
The cost-effectiveness of biopharmaceuticals: a look at the evidence. MAbs (2012) 0.75
Emerging trends in cancer care: health plans' and pharmacy benefit managers' perspectives on changing care models. Am Health Drug Benefits (2012) 0.75
A Quininib Analogue and Cysteinyl Leukotreine Receptor Antagonist inhibits VEGF-Independent Angiogenesis and Exerts an Additive Anti-angiogenic Response with Bevacizumab. J Biol Chem (2016) 0.75
Cutting the cost of cancer care. Gastrointest Cancer Res (2009) 0.75
Cancer care burden: aiming at the Achilles heel. Curr Oncol (2015) 0.75
Response to Michael Wonder's comments on the article 'Assessment of the therapeutic value of new medicines marketed in Australia'. J Pharm Policy Pract (2013) 0.75
Effect of discounting on estimation of benefits determined by hepatitis C treatment. World J Gastroenterol (2012) 0.75
A decision exercise to engage cancer patients and families in deliberation about Medicare coverage for advanced cancer care. BMC Health Serv Res (2014) 0.75
Surviving with lung cancer: medication-taking and oral targeted therapy. Geriatr Nurs (2014) 0.75
Challenging Perceptions About Oncology Product Pricing in Breast and Colorectal Cancer. Pharmaceut Med (2016) 0.75
Evolution of costs of cancer drugs in a Portuguese hospital. World J Clin Oncol (2014) 0.75
Reducing cancer costs and improving quality through collaboration with payers: a proposal from the Florida society of clinical oncology. J Oncol Pract (2010) 0.75
Health care's ills: A Catholic diagnosis. Linacre Q (2016) 0.75
How to develop treatments for biologically heterogeneous "diseases". Clin Cancer Res (2012) 0.75
Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute. Oncologist (2015) 0.75
Photodynamic therapy and imaging based on tumor-targeted nanoprobe, polymer-conjugated zinc protoporphyrin. Future Sci OA (2015) 0.75
New cancer drugs at the cost of bankruptcy: will the oncologist tell the patients the benefit in terms of days/weeks added to life? Oncologist (2014) 0.75
Why clinical oncologists should talk about the price of cancer drugs. Virtual Mentor (2013) 0.75
Oral cancer therapy: policy implications for the uninsured and underinsured populations. J Adv Pract Oncol (2013) 0.75
CT colonography for population screening of colorectal cancer: hints from European trials. Br J Radiol (2016) 0.75
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Cetuximab for the treatment of colorectal cancer. N Engl J Med (2007) 13.39
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol (2008) 9.98
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 8.73
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol (2009) 7.80
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol (2008) 5.56
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65
An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health (2009) 2.60
The $64,000 question--what is a quality-adjusted life-year worth? Clin Ther (2006) 1.52
Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial. Expert Rev Anticancer Ther (2008) 1.10
DALYs and QALYs in developing countries. Health Aff (Millwood) (2007) 1.08
The limitations of "vulnerability" as a protection for human research participants. Am J Bioeth (2004) 14.06
What makes clinical research in developing countries ethical? The benchmarks of ethical research. J Infect Dis (2004) 9.65
Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med (2005) 8.25
Dealing with the long-term social implications of research. Am J Bioeth (2011) 5.41
Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB (2003) 3.82
Enduring and emerging challenges of informed consent. N Engl J Med (2015) 3.79
Clinical trials and medical care: defining the therapeutic misconception. PLoS Med (2007) 3.77
Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med (2002) 3.62
Oversight of human participants research: identifying problems to evaluate reform proposals. Ann Intern Med (2004) 3.58
SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect Control Hosp Epidemiol (2010) 3.44
Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol (2006) 2.72
Informed Consent. N Engl J Med (2017) 2.56
Moral distress: a growing problem in the health professions? Hastings Cent Rep (2010) 2.23
A systematic review of the empirical literature evaluating IRBs: what we know and what we still need to learn. J Empir Res Hum Res Ethics (2011) 2.03
More than the money: a review of the literature examining healthy volunteer motivations. Contemp Clin Trials (2010) 1.92
Paying research subjects: an analysis of current policies. Ann Intern Med (2002) 1.90
The ethics of paying for children's participation in research. J Pediatr (2002) 1.80
Participants in phase 1 oncology research trials: are they vulnerable? Arch Intern Med (2008) 1.74
The invisible hand in clinical research: the study coordinator's critical role in human subjects protection. J Law Med Ethics (2002) 1.72
Ethical climate, ethics stress, and the job satisfaction of nurses and social workers in the United States. Soc Sci Med (2007) 1.72
The quality of informed consent: mapping the landscape. A review of empirical data from developing and developed countries. J Med Ethics (2012) 1.69
Why patients continue to participate in clinical research. Arch Intern Med (2008) 1.62
Research on stored biological samples: the views of Ugandans. IRB (2005) 1.59
Ethical considerations in HIV cure research: points to consider. Curr Opin HIV AIDS (2013) 1.55
Regional ethics organizations for protection of human research participants. Nat Med (2004) 1.48
Respondent burden in clinical research: when are we asking too much of subjects? IRB (2005) 1.37
Clinical research with economically disadvantaged populations. J Med Ethics (2007) 1.36
Does it pay to pay? A randomized trial of prepaid financial incentives and lottery incentives in surveys of nonphysician healthcare professionals. Nurs Res (2005) 1.32
Comprehension and informed consent: assessing the effect of a short consent form. IRB (2010) 1.30
Including persons with HIV infection in cancer clinical trials. J Clin Oncol (2008) 1.30
Money, coercion, and undue inducement: attitudes about payments to research participants. IRB (2012) 1.29
What should research participants understand to understand they are participants in research? Bioethics (2008) 1.27
Reciprocity and post-trial access for participants in antiretroviral therapy trials. AIDS (2006) 1.26
Quality of parental consent in a Ugandan malaria study. Am J Public Health (2005) 1.19
Enrolling pregnant women: issues in clinical research. Womens Health Issues (2013) 1.13
The quality of informed consent in a clinical research study in Thailand. IRB (2005) 1.13
Points to consider: The research ethics consultation service and the IRB. IRB (2009) 1.13
Views of adolescents and parents on pediatric research without the potential for clinical benefit. Pediatrics (2012) 1.11
When to start ART in Africa. N Engl J Med (2013) 1.09
Planning for posttrial access to antiretroviral treatment for research participants in developing countries. Am J Public Health (2009) 1.06
Quality improvement and ethical oversight. Ann Intern Med (2007) 1.06
Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation. Br J Haematol (2007) 1.01
Misconceptions about coercion and undue influence: reflections on the views of IRB members. Bioethics (2012) 1.00
Ethics of clinical research in the developing world. Nat Rev Immunol (2002) 0.99
Does fear of retaliation deter requests for ethics consultation? Med Health Care Philos (2007) 0.96
Randomization to standard and concise informed consent forms: development of evidence-based consent practices. Contemp Clin Trials (2012) 0.95
Nurse Practitioners' attitudes about cancer clinical trials and willingness to recommend research participation. Contemp Clin Trials (2011) 0.95
Conducting HIV research in racial and ethnic minority communities: building a successful interdisciplinary research team. J Assoc Nurses AIDS Care (2011) 0.94
Post-trial access to tested interventions: the views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study. AIDS Res Hum Retroviruses (2006) 0.94
Exploring decision-making of HIV-infected Hispanics and African Americans participating in clinical trials. J Assoc Nurses AIDS Care (2011) 0.93
"Special scrutiny": a targeted form of research protocol review. Ann Intern Med (2004) 0.92
Financial incentives and response rates in nursing research. Nurs Res (2004) 0.91
Circumcision and HIV prevention research: an ethical analysis. Lancet (2006) 0.90
Introduction: the Fogarty International Research Ethics Education and Curriculum Development Program in historical context. J Empir Res Hum Res Ethics (2013) 0.90
Ethical conflict in nurse practitioners and physician assistants in managed care. Nurs Res (2006) 0.89
Commonly performed procedures in clinical research: a benchmark for payment. Contemp Clin Trials (2012) 0.88
Clinical research enrolling pregnant women: a workshop summary. J Womens Health (Larchmt) (2011) 0.88
Everyday ethics: ethical issues and stress in nursing practice. J Adv Nurs (2010) 0.85
A consent form template for phase I oncology trials. IRB (2009) 0.84
Case study. Is longer always better? Commentary. Hastings Cent Rep (2008) 0.83
Predictors of ethical stress, moral action and job satisfaction in health care social workers. Soc Work Health Care (2008) 0.83
Informed consent: practices and views of investigators in a multinational clinical trial. IRB (2006) 0.83
Enduring and emerging challenges of informed consent. N Engl J Med (2015) 0.82
Benefits and burdens of participation in a longitudinal clinical trial. J Empir Res Hum Res Ethics (2009) 0.82
Personal and community benefits and harms of research: views from Rakai, Uganda. AIDS (2007) 0.82
The ethics of placebo-controlled trials: methodological justifications. Contemp Clin Trials (2013) 0.82
The nursing shortage and the quality of care. N Engl J Med (2002) 0.81
Empirical evaluation of the need for 'on-going consent' in clinical research. AIDS (2011) 0.81
Institutional Review Boards: Purpose and Challenges. Chest (2015) 0.80
Making the transition to a learning health care system. Commentary. Hastings Cent Rep (2013) 0.79
To friend or not to friend: the use of social media in clinical oncology. J Oncol Pract (2011) 0.78
Research vulnerability and patient advocacy: balance-seeking perspectives for the clinical nurse scientist? Nurs Res (2002) 0.78
Informed consent and patient registry for the rare disease community: Editorial. Contemp Clin Trials (2011) 0.78
Four paradigms of clinical research and research oversight. Camb Q Healthc Ethics (2007) 0.78
Perceptions of appropriateness of care in the intensive care unit. JAMA (2012) 0.75
Beneficent deception: whose best interests are we serving? Am J Bioeth (2004) 0.75
Informing egg donors of the potential for embryonic research: a survey of consent forms from U.S. in vitro fertilization clinics. Fertil Steril (2011) 0.75
The ethics of empowering patients as partners in healthcare-associated infection prevention. Infect Control Hosp Epidemiol (2014) 0.75
Correction in response to the review of ethical issues in international biomedical research. Dev World Bioeth (2009) 0.75
The Role of the Virtuous Investigator in Protecting Human Research Subjects. Perspect Biol Med (2016) 0.75
Research mentors: an understated value? Nurs Res (2003) 0.75
Nurses and Industry: Conflict or Collaboration? Ann Intern Med (2016) 0.75
In memoriam: Alan Wertheimer. Hastings Cent Rep (2015) 0.75
Palliative care: a supportive adjunct to pediatric phase I clinical trials for anticancer agents? Pediatrics (2004) 0.75
Ethical issues in cancer chemoprevention trials: considerations for IRBs and investigators. IRB (2007) 0.75
Emergency Nursing, Ebola, and Public Policy: The Contributions of Nursing to the Public Policy Conversation. Hastings Cent Rep (2016) 0.75
Making the Choices Necessary to Make a Difference: The Responsibility of National Bioethics Commissions. Hastings Cent Rep (2017) 0.75
Cultivating Synergy in Nursing, Bioethics, and Policy. Hastings Cent Rep (2016) 0.75
Surgical medicine: imperfect and extraordinary. Narrat Inq Bioeth (2015) 0.75